Pazopanib for the treatment of soft-tissue sarcoma
Posted: Sat Sep 19, 2015 9:10 am
Clin Pharmacol. 2012; 4: 65–70.
Published online 2012 Oct 26. doi: 10.2147/CPAA.S33195
PMCID: PMC3508654
Pazopanib for the treatment of soft-tissue sarcoma
Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 and Isabelle Ray-Coquard1,5
Author information ► Copyright and License information ►
Abstract
Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.
Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitor
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508654/
Published online 2012 Oct 26. doi: 10.2147/CPAA.S33195
PMCID: PMC3508654
Pazopanib for the treatment of soft-tissue sarcoma
Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 and Isabelle Ray-Coquard1,5
Author information ► Copyright and License information ►
Abstract
Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.
Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitor
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508654/